Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
106
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience

Masuho Saburia Department of Hematology, Oita Prefectural Hospital, Oita City, JapanCorrespondence[email protected]
,
Masanori Sakataa Department of Hematology, Oita Prefectural Hospital, Oita City, Japan
,
Hiroyuki Takataa Department of Hematology, Oita Prefectural Hospital, Oita City, Japan
,
Yasuhiko Miyazakia Department of Hematology, Oita Prefectural Hospital, Oita City, Japan
,
Katsuya Kawanob Department of Clinical Laboratory Technology, Oita Prefectural Hospital, Oita City, Japan
,
Hitohiro Sasakic Department of Hematology, Oita Kouseiren Tsurumi Hospital, Japan
,
Miyuki Abec Department of Hematology, Oita Kouseiren Tsurumi Hospital, Japan
,
Kazuhiro Kohnoc Department of Hematology, Oita Kouseiren Tsurumi Hospital, Japan
,
Yasuhiro Sogad Department of Clinical Laboratory, Oita Kouseiren Tsurumi Hospital, Japan
,
Kentaro Nagamatsue Department of Hematology, Almeida Memorial Hospital, Oita, Japan
,
Keiji Onoe Department of Hematology, Almeida Memorial Hospital, Oita, Japan
,
Toshiyuki Nakayamac Department of Hematology, Oita Kouseiren Tsurumi Hospital, Japan
&
Eiichi Ohtsukaa Department of Hematology, Oita Prefectural Hospital, Oita City, Japan
 show all
Pages 2691-2695 | Received 14 Jan 2022, Accepted 27 May 2022, Published online: 10 Jun 2022

References

  • Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–912.
  • Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer. 2009;115(24):5734–5739.
  • Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.
  • Granell M, Calvo X, Garcia-Guiñón A, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(6):1099–1104.
  • Ganzel C, Rouvio O, Avivi I, et al. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome. Leuk Res. 2018;68:9–14.
  • Katodritou E, Terpos E, Delimpasi S, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek myeloma study group. Blood Cancer J. 2018;8:31.
  • Gundesen MT, Lund T, Moeller HEH, et al. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol Rep. 2019;21(1):8.
  • Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
  • Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
  • Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia. 2013;27(4):780–791.
  • Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–233.
  • Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Bhutani M, Foureau DM, Atrash S, et al. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1–20.
  • Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the intergroupe francophone du myélome. J Clin Oncol. 2016;34(18):2125–2132.
  • Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28(1):222–225.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.